Literature DB >> 3092968

Ketanserin in the treatment of traumatic vasospastic disease.

V H Larsen, J Fabricius, G Nielsen, K S Hansen.   

Abstract

The specific serotonin receptor blocker ketanserin was given orally to 12 patients with traumatic vasospastic disease in a double blind crossover study. The effect of treatment was assessed by measuring finger systolic pressure and rewarming time after cold provocation and by medical interview and diaries. Median (range) percentage change in finger systolic pressure after cooling was 50 (0-100)% after treatment with ketanserin compared with 0 (0-90)% after placebo. Median (range) rewarming time after cooling decreased from 320 (236-972)s with placebo to 160 (88-404)s after treatment with ketanserin. These changes were not significant. Ninety five percent confidence intervals for difference between the treatments, however, showed that finger systolic pressure may be 80% better and rewarming time 256 seconds faster after treatment with ketanserin than after placebo. The number of attacks did not differ significantly between the two treatments. Two patients had a feeling of warmth in their hands during treatment with ketanserin. The results suggest that orally administered ketanserin may improve digital circulation in patients with traumatic vasospastic disease, but larger numbers of patients are required to assess the true effect of treatment with ketanserin in this disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3092968      PMCID: PMC1341509          DOI: 10.1136/bmj.293.6548.650

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  5 in total

1.  Clinical biostatistics. XXXIV. The other side of 'statistical significance': alpha, beta, delta, and the calculation of sample size.

Authors:  A R Feinstein
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials.

Authors:  J A Freiman; T C Chalmers; H Smith; R R Kuebler
Journal:  N Engl J Med       Date:  1978-09-28       Impact factor: 91.245

Review 3.  Raynaud syndrome.

Authors:  R J Blunt; J M Porter
Journal:  Semin Arthritis Rheum       Date:  1981-05       Impact factor: 5.532

4.  Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.

Authors:  O K Roald; E Seem
Journal:  Br Med J (Clin Res Ed)       Date:  1984-09-08

5.  Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.

Authors:  E Stranden; O K Roald; K Krohg
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-16
  5 in total
  1 in total

1.  Diagnostic tests in Raynaud's phenomena in workers exposed to vibration: a comparative study.

Authors:  N Olsen
Journal:  Br J Ind Med       Date:  1988-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.